Exocrine Pancreatic Insufficiency Treatment Market – By Treatment, By Drug Type, By Symptom, By Distribution Channel – Global Forecast, 2024 – 2032

Exocrine Pancreatic Insufficiency Treatment Market Size

The global exocrine pancreatic insufficiency treatment market size was valued at around USD 2.7 billion in 2023 and is estimated to grow at 5.6% CAGR from 2024 to 2032. Exocrine pancreatic insufficiency (EPI) treatment refers to the medical and dietary management strategies used to address the deficiency of exocrine pancreatic enzymes, which are crucial for the digestion and absorption of nutrients. EPI treatment aims to alleviate symptoms, improve nutrient absorption, and enhance the overall quality of life for affected individuals.
 

The rising prevalence of chronic pancreatitis (CP) and cystic fibrosis (CF) is a key catalyst for the exocrine pancreatic insufficiency (EPI) treatment market, as both conditions severely impair pancreatic function, leading to enzyme deficiencies and digestion issues. For instance, the Cystic Fibrosis Foundation reports that nearly 40,000 children and adults in the U.S. are living with CF, with an estimated 105,000 individuals diagnosed across 94 countries. CF affects people of all racial and ethnic backgrounds, necessitating long-term treatment through pancreatic enzyme replacement therapy (PERT). Therefore, as the prevalence of these conditions increases, so does the demand for effective treatment options such as PERT to manage digestive health.
 

Furthermore, advancements in diagnostic techniques for exocrine pancreatic insufficiency (EPI) are significantly enhancing the detection of the condition, leading to more timely and effective treatment. Recent research has focused on identifying specific biomarkers to improve the accuracy of pancreatic function assessments. A key biomarker, fecal elastase-1, is commonly used to evaluate exocrine function, with low levels in stool samples serving as a strong indicator of pancreatic insufficiency. This improved diagnostic precision is essential for the accurate diagnosis and management of EPI, stimulating market growth.
 

Exocrine Pancreatic Insufficiency Treatment Market Trends

• The exocrine pancreatic insufficiency (EPI) treatment market is largely accelerated by the growing aging population base. The global demographic landscape is shifting toward an older population, increasing the prevalence of age-related health conditions, including those leading to EPI, and boosting the demand for pancreatic enzyme replacement therapy (PERT).
   
• According to the World Health Organization (WHO), the global population aged 60 and over is projected to grow from 1 billion in 2020 to 1.4 billion by 2030, eventually doubling to 2.1 billion by 2050. Furthermore, the number of individuals aged 80 and older is expected to triple by 2050, reaching 426 million.
   
• Therefore, this demographic trend highlights the increasing need for effective treatments that address age-related health conditions such as EPI, further propelling the growth of the PERT market.
   

Exocrine Pancreatic Insufficiency Treatment Market Analysis

Based on treatment, the market is divided into nutritional management and pancreatic enzyme replacement therapy (PERT). The pancreatic enzyme replacement therapy (PERT) segment dominated the market with the largest revenue of USD 2.3 billion in 2023 and is expected to grow at a significant CAGR over the forecast period.
 

• Pancreatic enzyme replacement therapy effectively addresses exocrine pancreatic insufficiency (EPI) by boosting nutrient absorption, alleviating gastrointestinal issues such as bloating and steatorrhea, and enhancing overall quality of life.
   
• PERT restores the body’s ability to digest fats, proteins, and carbohydrates, thereby preventing complications such as malnutrition, vitamin deficiencies, and unintended weight loss.
   
• Additionally, with flexible dosages for precision medicine—which is estimated to reach USD 157.1 billion by 2032—PERT is generally well-tolerated and exhibits minimal side effects. Available in user-friendly capsule or tablet forms, PERT seamlessly fits into daily routines.
   
• Advanced tablet coatings, such as enteric-coated formulations, protect the enzymes from stomach acid, ensuring their effective release in the intestine.
   
• Thus, PERT emerges as a crucial long-term strategy for managing EPI and improving patient outcomes, thereby driving industry expansion.
   

Based on drug type, the exocrine pancreatic insufficiency treatment market is bifurcated into Creon, Zenpep, Pancreaze, Viokace, and other drug types. The Creon segment is projected to account for the largest revenue size of USD 3.6 billion by 2032.
 

• Creon, a leading pancreatic enzyme replacement therapy (PERT), combines lipase, protease, and amylase enzymes, which play a crucial role in breaking down fats, proteins, and carbohydrates. This combination enhances nutrient absorption and alleviates symptoms such as bloating, steatorrhea, and malnutrition.
   
• The enteric-coated capsules of Creon protect the enzymes from stomach acid, ensuring their optimal release in the small intestine. Available in multiple dosages, Creon allows for tailored treatments to meet individual patient needs.
   
• Generally well-tolerated with minimal side effects, Creon not only boosts digestive function but also significantly improves the quality of life for patients with EPI, promoting better nutrition and preventing complications linked to poor digestion.
   
• Therefore, Creon stands as a vital treatment for managing EPI, offering patients a practical and effective solution to regain control over their digestive health.
   

Based on symptom, the exocrine pancreatic insufficiency treatment market is bifurcated into abdominal pain, constipation, diarrhea, fatty stools, weight loss, and other symptoms. The diarrhea segment is projected to grow at a CAGR of 5.9% during the forecast period to reach USD 1.2 billion by 2032.
 

• Diarrhea is a common symptom of exocrine pancreatic insufficiency (EPI) and serves as a key indicator, often leading to early diagnosis and treatment. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), approximately 30% of EPI patients experience chronic diarrhea.
   
• By managing diarrhea through pancreatic enzyme replacement therapy (PERT) or dietary changes, patients can experience improved nutrient absorption and digestion, which, in turn, reduces the frequency and severity of bowel disturbances.
   
• Properly addressing diarrhea not only enhances the overall health of EPI patients but also mitigates the risks of dehydration and malnutrition, ultimately improving their quality of life by stabilizing gastrointestinal function.
   
• Therefore, effectively managing diarrhea in EPI patients is critical for optimizing nutrient absorption and maintaining digestive health.
   
• By addressing this key symptom through timely interventions, such as PERT and dietary adjustments, healthcare providers can significantly reduce the risk of complications, thereby improving patients' overall quality of life and long-term outcomes.
   

Based on distribution channel, the exocrine pancreatic insufficiency treatment market is bifurcated into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is projected to grow at a CAGR of 5.4% during the forecast period.
 

• Hospital pharmacies play a pivotal role in treating exocrine pancreatic insufficiency (EPI), ensuring patients have timely access to essential medications, such as pancreatic enzyme replacement therapy (PERT).
   
• By collaborating closely with healthcare providers, these pharmacies customize dosages and formulations to meet each patient's unique needs.
   
• Hospital pharmacists provide crucial guidance on medication usage, emphasizing administration with meals and managing potential side effects to achieve optimal therapeutic outcomes.
   
• Furthermore, these pharmacies expedite access to specialized treatments and prioritize patient education, enhancing medication adherence and improving the overall quality of care for EPI patients. This underscores the critical role of hospital pharmacies in managing the condition and propelling market growth.
   

North America exocrine pancreatic insufficiency treatment market accounted for a 56.9% revenue share in 2023 and is expected to experience substantial growth reaching USD 2.4 billion by 2032.
 

• North America stands at the forefront of treating exocrine pancreatic insufficiency (EPI), bolstered by its advanced healthcare infrastructure, pioneering research, and broad access to pancreatic enzyme replacement therapy (PERT).
   
• Furthermore, North America's esteemed medical research institutions propel continuous innovation in EPI diagnostics and therapies, paving the way for more effective and tailored treatments.
   
• Coupled with established healthcare systems and comprehensive insurance coverage, these factors enhance patient access to specialized care and medications, leading to improved outcomes for those with EPI, thus accelerating market growth.
   

The exocrine pancreatic insufficiency treatment market in UK is expected to experience significant and promising growth from 2024 to 2032.
 

• The increasing prevalence of chronic conditions, such as chronic pancreatitis and cystic fibrosis, both of which lead to EPI, is contributing to a larger patient base requiring long-term treatment through pancreatic enzyme replacement therapy (PERT).
   
• Additionally, the aging population in the UK is on the rise, with a growing number of individuals suffering from age-related health issues that can result in pancreatic insufficiency, further boosting demand for EPI treatments.
   

Japan exocrine pancreatic insufficiency treatment market is anticipated to witness lucrative growth between 2024 and 2032.
 

• Rapid economic growth in Japan is driving increased healthcare spending and a stronger focus on improving health outcomes, significantly benefiting the exocrine pancreatic insufficiency (EPI) treatment market. This economic development supports investments in advanced therapies and healthcare technologies tailored to managing EPI, ensuring that the latest innovations are accessible to patients who require them.
   
• Additionally, the growing adoption of telemedicine and digital health solutions in Japan is enhancing patient engagement and access to care. Remote consultations and monitoring allow EPI patients to better manage their condition, improving adherence to treatment plans and leading to more positive health outcomes. This integration of technology with healthcare is expected to further propel the growth of the EPI treatment market in Japan.
   

The exocrine pancreatic insufficiency treatment market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.
 

• The exocrine pancreatic insufficiency (EPI) treatment market in Saudi Arabia is poised for growth due to improved healthcare infrastructure and rising awareness of pancreatic diseases, which facilitate earlier diagnoses. Enhanced diagnostic capabilities enable more patients to identify EPI, subsequently increasing the demand for treatment.
   
• Additionally, the Saudi government's Vision 2030 initiative aims to expand healthcare services, improving access to EPI treatments for chronic disease patients.
   
• Therefore, these factors are expected to significantly propel the growth of the EPI treatment market in the coming years, enhancing patient outcomes and overall healthcare quality in the region.
   

Exocrine Pancreatic Insufficiency Treatment Market Share

The exocrine pancreatic insufficiency (EPI) treatment sector is highly consolidated, featuring a blend of major global pharmaceutical companies and smaller to medium-sized firms vying for market share. A crucial aspect of market strategy involves the continuous introduction of innovative enzyme replacement therapies and other treatment modalities utilizing advanced technologies. Prominent industry players wield significant influence in this dynamic landscape, often driving progress through substantial investments in research and development focused on enhancing treatment efficacy and patient adherence. Additionally, strategic alliances, partnerships, and mergers play a vital role in strengthening market positions and expanding their global presence, particularly in response to evolving regulatory frameworks and increasing patient demand for effective EPI solutions.
 

Exocrine Pancreatic Insufficiency Treatment Market Companies

Some of the eminent market participants operating in the exocrine pancreatic insufficiency treatment industry include:

• Abbott Laboratories
• AbbVie
• Digestive Care
• Essential Pharma
• Nestle
• Nordmark Pharma
• Sun Pharmaceutical Industries
• Viatris
• Vivus
• Zentiva Pharma UK
   

Exocrine Pancreatic Insufficiency Treatment Industry News:

• In February 2023, Nestle Health and Codexis, Inc. announced positive Phase 1 results for CDX-7108, validating their collaboration and strengthening their position in enzyme therapy ahead of the planned Phase 2 study in early 2024.
   
• In January 2020, Nestlé S.A. announced that it had entered into an asset purchase agreement with Allergan plc to acquire the gastrointestinal medication Zenpep. This acquisition was aimed at strengthening Nestlé S.A.'s medical nutrition business and expanding its portfolio of therapeutic products.
   

The exocrine pancreatic insufficiency treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment

• Nutritional management
• Pancreatic enzyme replacement therapy (PERT) 

Market, By Drug Type

• Creon
• Zenpep
• Pancreaze
• Viokace
• Other drug types               

Market, By Symptom

• Abdominal pain
• Constipation
• Diarrhea
• Fatty stools
• Weight loss
• Other symptoms                        

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies                      

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE